ERBB2 and breast carcinoma: Here, we specifically focused on HER2+ breast cancer cells based on our previous studies demonstrating the pathogenesis of this cancer subtype responsive to dysregulated NO levels and their great sensitivity to SEP treatment (21, 22, 54).